nach oben

Erschienen in:

01.07.2023 | News item

Semaglutide, liraglutide: risk of suicidal ideation and self-injury

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is reviewing data on the risk of suicidal ideation and self-injury with glucagon-like peptide-1 (GLP-1) receptor agonists including Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide). The three drugs are used for the treatment of type 2 diabetes mellitus, and Saxenda and Wegovy are also authorised for weight management. …

EMA statement on ongoing review of GLP-1 receptor agonists Internet Document : 11 Jul 2023. Available from: URL: https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists

Titel: Semaglutide, liraglutide: risk of suicidal ideation and self-injury
Publikationsdatum: 01.07.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-43459-0

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Immunotherapies

Anakinra/interleukin 1 beta inhibitors/tocilizumab

Micafungin/voriconazole

Olmesartan-medoxomil/hydrochlorothiazide

Warfarin

COVID-19 vaccine-related autoimmune haemolytic anaemia